The deal is expected to strengthen Lupin’s presence in the Japanese market.
Lupin president (Asia Pacific, Middle East, Africa and Latin America) Vinod Dhawan said the acquisition would provide them access to $11b market through I’rom’s well established hold in the DPC (diagnosis procedure combination) hospital segment.
The financial details of the acquisition have not been disclosed.